CompletedNot Applicable

Pre-emptive Treatments in Lupus Nephritis Patients With Serological Reactivation

Hong Kong49 participantsStarted 2016-04-21

Plain-language summary

The optimal management of asymptomatic serological reactivation (ASR) in lupus nephritis (LN) patients remained undefined. This project aims to investigate the impact of pre-emptive treatment on disease relapse in LN patients who experienced ASR.

Who can participate

Age range18 Years – 90 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Increase in anti-dsDNA to \>100 IU/mL, with or without drop in serum complement levels OR
✓. Increase in anti-dsDNA to higher than the normal range and more than two times of the preceding value, with or without drop in serum complement levels
✓. Absence of renal or systemic manifestation of SLE.

Exclusion criteria

✕. Patients who cannot provide informed consent.
✕. Patients whom the clinicians opined to have excessively high risk of infection or malignancy.
✕. Patients who are pregnant or lactating.

What they're measuring

Renal Flare

Timeframe: Within 24 months

Trial details

NCT IDNCT04870359

SponsorThe University of Hong Kong

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-03-31

View on ClinicalTrials.gov More Lupus Nephritis trials